MX2020002247A - Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. - Google Patents

Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.

Info

Publication number
MX2020002247A
MX2020002247A MX2020002247A MX2020002247A MX2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A MX 2020002247 A MX2020002247 A MX 2020002247A
Authority
MX
Mexico
Prior art keywords
gnrh
derivative
pharmaceutical composition
composition containing
palmitic acid
Prior art date
Application number
MX2020002247A
Other languages
English (en)
Inventor
Dong Kyu Jin
Original Assignee
Novel Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novel Pharma Inc filed Critical Novel Pharma Inc
Publication of MX2020002247A publication Critical patent/MX2020002247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un derivado de la hormona liberadora de gonadotropina (GnRH) conjugado a ácido palmítico de larga duración y una composición farmacéutica que lo contiene. Se espera que un derivado de GnRH de la presente invención contribuya bastante, a través de excelente biodisponibilidad y vida media incrementada en la sangre, a la reducción en frecuencia de dosificación de fármacos y dosis y similares en el tratamiento de las enfermedades dependientes a la hormona sexual. Particularmente, el derivado de GnRH puede solucionar las desventajas de las preparaciones de liberación sostenida de GnRH existentes, las cuales tienen los efectos laterales de sensación residual y dolor en el sitio de inyección.
MX2020002247A 2017-09-27 2018-06-20 Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. MX2020002247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170125291 2017-09-27
PCT/KR2018/006954 WO2019066199A1 (ko) 2017-09-27 2018-06-20 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2020002247A true MX2020002247A (es) 2021-03-25

Family

ID=65903631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002247A MX2020002247A (es) 2017-09-27 2018-06-20 Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.

Country Status (11)

Country Link
US (1) US10994018B2 (es)
EP (1) EP3639856B1 (es)
JP (1) JP6800372B2 (es)
KR (2) KR102072164B1 (es)
CN (1) CN111093709B (es)
AU (1) AU2018338924B2 (es)
CA (1) CA3075252C (es)
ES (1) ES2925946T3 (es)
MX (1) MX2020002247A (es)
RU (2) RU2746566C2 (es)
WO (1) WO2019066199A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955181A (zh) 2019-03-26 2021-06-11 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
KR102020788B1 (ko) 2019-03-29 2019-09-11 위월드 주식회사 다수의 위성 환경에서의 위성 추적 안테나 시스템 및 이를 이용한 위성 추적 방법
JP2023532107A (ja) * 2020-06-30 2023-07-26 チョン クン ダン ファーマシューティカル コーポレーション Ｇｎｒｈ誘導体を含む注射用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045625A (ja) * 1996-04-30 1998-02-17 Takeda Chem Ind Ltd 医薬組成物
CA2250908C (en) 1996-04-30 2012-03-13 Takeda Chemical Industries, Ltd. Combined use of gnrh agonist and antagonist
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
WO2004030650A2 (de) 2002-09-27 2004-04-15 Zentaris Gmbh Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung
WO2005067889A1 (en) 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
US20080027003A1 (en) * 2004-05-27 2008-01-31 Curepeptide Ltd. Peptides Useful for Treating Gnrh Associated Diseases
RU2325160C1 (ru) * 2006-07-31 2008-05-27 Ефаг АО Средство для лечения рака предстательной железы и профилактики его рецидива
EP2946770A1 (en) * 2008-08-29 2015-11-25 Genzyme Corporation Controlled-released peptide formulations
US20130060004A1 (en) * 2010-05-07 2013-03-07 Ananda Kuppanna Novel Process For The Preparation Of Leuprolide And Its Pharmaceutically Acceptable Salts Thereof
JP6143740B2 (ja) * 2011-04-07 2017-06-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 持続性ペプチド類似体
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
US9150615B2 (en) * 2013-12-18 2015-10-06 Scinopharm Taiwan, Ltd. Process for the preparation of leuprolide and its pharmaceutically acceptable salts
CN105797134B (zh) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 一种难溶亮丙瑞林缓释制剂

Also Published As

Publication number Publication date
EP3639856A4 (en) 2021-03-10
EP3639856A1 (en) 2020-04-22
RU2020109232A3 (es) 2020-10-16
US10994018B2 (en) 2021-05-04
ES2925946T3 (es) 2022-10-20
AU2018338924A1 (en) 2020-02-06
AU2018338924B2 (en) 2020-05-21
RU2020109232A (ru) 2020-04-20
CN111093709A (zh) 2020-05-01
CA3075252C (en) 2020-12-08
RU2746566C2 (ru) 2021-04-15
CA3075252A1 (en) 2019-04-04
JP6800372B2 (ja) 2020-12-16
CN111093709B (zh) 2021-11-12
US20200268896A1 (en) 2020-08-27
RU2020104475A (ru) 2021-08-02
KR20200011535A (ko) 2020-02-03
KR102072164B1 (ko) 2020-02-03
WO2019066199A1 (ko) 2019-04-04
KR20190036449A (ko) 2019-04-04
JP2020528070A (ja) 2020-09-17
EP3639856B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
HRP20200991T1 (hr) Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate
MX2020002247A (es) Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
MX345942B (es) Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2021002083A (es) Composiciones farmaceuticas que contienen insulina.
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
EA201792591A1 (ru) Фармацевтические препараты
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
MX2021009526A (es) Composiciones para suministro farmacologico, para la administracion ocular de agentes terapeuticos, y metodos de uso de las mismas.
EA201992020A1 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
EA201590847A1 (ru) Новые ингибиторы rock
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2018211336A3 (en) Solid dosage form containing sorafenib tosylate
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
MX2020013206A (es) Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.